Medicinal cannabis studies

CACOS Study

The CACOS Study is an observational study being run through the CA Clinics network.

  • Study Name: CA Clinics Observational Study (CACOS)
  • Study Type: Observational
  • Objective: To collect data about safety and efficacy of medicinal cannabis treatments in Australia using patient reported outcome (PRO) measures
  • Indications Assessed: The CACOS study encompasses a number of refractory indications in combined and parallel study-arms including but not limited to: Chronic pain conditions (including endometriosis, fibromyalgia, and neuropathy); Psychiatric conditions (including anxiety and PTSD) and Neurological conditions (including epilepsy).
  • Enrolment: Patients can be enrolled in the study through referral to CA Clinics by their treating GP or specialist.

Please find the CA clinics referral form here.

Eligibility Criteria:
  • Males and Females aged 18 years and above
  • Deemed suitable for medicinal cannabis treatments by CA Clinics prescribing doctor
  • Willing and able to provide informed consent

This study has been approved by Bellberry Human Research Ethics Committee.

Register Interest

CA Clinics partner with treating cannabis doctors and specialists to provide medicinal cannabis treatment alternatives via the TGA Special Access Scheme that doctors might include in their patients cannabis treatment plan.

CMOS Study

The CMOS Study is an observational study that will be run in collaboration with GP’s and specialists around Australia. This study aims to recruit 20,000 Australian patients undergoing treatment with medicinal cannabis.

The CMOS Study will benefit participating clinicians, and their patients, by providing insight into medicinal cannabis prescribing and treatment practices from clinics around Australia participating in CMOS. Insights will be provided in the form of de-identified aggregated data reports including information on product dosing/categories being prescribed, patient reported outcomes (PROs) and adverse events reported by study participants, to be released to participating clinics on a quarterly basis. 

This data will provide a useful resource for clinicians who may be prescribing medicinal cannabis products and wish to gain better insight into the current Australian prescribing landscape.

  • Study Name: Cannabinoid Medicine Observational Study (CMOS)
  • Study Type: Observational
  • Objective: Collect data about safety and efficacy of medicinal cannabis products in treatment of refractory indications, as well as data on effective dosage and effects of medicinal cannabis treatment on concomitant medication use.
  • Indications Assessed: The CMOS study will encompass a range of refractory conditions, including but not limited to: chronic pain conditions, neurological disorders, cancer pain and symptom management, psychiatric disorders, sleep disorders, palliative care, inflammatory conditions, gastrointestinal disorders, movement disorders and respiratory conditions.
  • Enrolment: Patients will be able to be enrolled in the study directly by their treating clinician (GP or specialist)
Eligibility Criteria:
  • – Deemed suitable for medicinal cannabis treatments by an Australian registered GP or specialist
  • – Willing and able to provide informed consent

Due to external factors affecting the enrolment of patients at CMOS study sites, Applied Cannabis Research have decided to close new patient enrolments until further notice. Patients who are already enrolled in the study will continue to be supported by CMOS (July 2021).

Learn more